Swiss Pharma, Biotech, Nutrition, And Specialty Ingredients Supplier Lonza Group's Proposed Bonds Rated 'BBB+' - S&P Global Ratings’ Credit Research

Swiss Pharma, Biotech, Nutrition, And Specialty Ingredients Supplier Lonza Group's Proposed Bonds Rated 'BBB+'

Swiss Pharma, Biotech, Nutrition, And Specialty Ingredients Supplier Lonza Group's Proposed Bonds Rated 'BBB+' - S&P Global Ratings’ Credit Research
Swiss Pharma, Biotech, Nutrition, And Specialty Ingredients Supplier Lonza Group's Proposed Bonds Rated 'BBB+'
Published Apr 06, 2020
3 pages (1430 words) — Published Apr 06, 2020
Price US$ 150.00  |  Buy this Report Now

About This Report

  
Abstract:

PARIS (S&P Global Ratings) April 6, 2020--S&P Global Ratings today assigned its 'BBB+' issue rating to Lonza Finance International N.V.'s proposed fixed-rate senior unsecured bonds. We understand the company will use the proceeds to refinance existing debt and for general corporate purposes. The size and maturity of the bonds will be subject to market conditions. The bonds will rank pari passu with other senior unsecured debt instruments. Lonza Group Ltd. (BBB+/Stable/--), the group's top holding company will provide an unconditional and irrevocable guarantee for the bonds. The group's 2019 results stem from the strong growth momentum on PBN (Pharma, Biotech, Nutrition) mainly in the mammalian and microbial segments. This led to an increase in profitability (core EBITDA) to 1.6 billion

  
Report Type:

Ratings Action

Issuer
Lonza Finance International N.V.
Sector
Global Issuers
Country
Region
Europe, Middle East, Africa
Format:
PDF Adobe Acrobat
Buy Now

Lonza Group Ltd. – 2023/04/11 – US$ 500.00

Tear Sheet: Lonza Group AG – 2024/11/12 – US$ 500.00

Lonza Group AG – 2025/05/14 – US$ 500.00

More from S&P Global Ratings’ Credit Research

S&P Global Ratings’ Credit Research—S&P Global Ratings’ credit research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P Global Ratings also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.

About the Author


Cite this Report

  
MLA:
S&P Global Ratings’ Credit Research. "Swiss Pharma, Biotech, Nutrition, And Specialty Ingredients Supplier Lonza Group's Proposed Bonds Rated 'BBB+'" Apr 06, 2020. Alacra Store. May 23, 2025. <http://www.alacrastore.com/s-and-p-credit-research/Swiss-Pharma-Biotech-Nutrition-And-Specialty-Ingredients-Supplier-Lonza-Group-s-Proposed-Bonds-Rated-BBB-2407916>
  
APA:
S&P Global Ratings’ Credit Research. (). Swiss Pharma, Biotech, Nutrition, And Specialty Ingredients Supplier Lonza Group's Proposed Bonds Rated 'BBB+' Apr 06, 2020. New York, NY: Alacra Store. Retrieved May 23, 2025 from <http://www.alacrastore.com/s-and-p-credit-research/Swiss-Pharma-Biotech-Nutrition-And-Specialty-Ingredients-Supplier-Lonza-Group-s-Proposed-Bonds-Rated-BBB-2407916>
  
US$ 150.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.